Treatment of Liver Diseases with a Multi-Gene Targeting Approach Metadichol

Liver diseases are becoming a major health concern. In the developing countries it is due to microbial infection. In the rest of the developed world it is due to alcohol abuse. Chronic liver disease and cirrhosis are a significant health concern in western countries. It is the fifth most common cause of death, after heart disease, cancer, stroke, and chest disease. The liver is capable of regeneration, but it can be overwhelmed leading to liver diseases like cirrhosis and hepatocellular cancer (HCC). Vitamin D levels are low in most patients with liver diseases, and this suggests possible therapeutic benefits with use of vitamin D or its analogues. Vitamin D, through the vitamin D nuclear-40 receptor (VDR) plays a crucial role in mineral ion homeostasis. The liver has a central in vitamin D synthesis and there is a need for an agent that will not lead to hypercalcemia. Metadichol, a nano emulsion of long-chain alcohols derived from food, is an inverse agonist of Vitamin D. In Diabetic rat studies, it is inhibits TNF alpha, ICAM1 (intracellular adhesion molecule), CCL2 (chemokine (C-C motif) is also referred to as monocyte chemoattractant protein 1 (MCP1). All these cytokines, chemokines are known to have important role in liver diseases. We show that Metadichol indeed does work in liver disease patients by normalizing essential liver enzymes ALT, AST and ALP, and GGT. This approach is a example where Metadichol targets multiple genes and via multiple pathways to bring about homeostasis of the liver and is a useful, safe, nontoxic product in treating liver diseases and alleviating a global threat.

Liver diseases are a worldwide problem. Нe number of drugs for treating liver diseases is small in number. Нere is a need for a safe and therapeutic treatment with new molecular entities . The liver helps purify the blood. It produces albumin as well as the proteins that cause blood clotting. Нe liver stores sugar appropriately, fats and vitamins until they are needed elsewhere in the body and also manufactures fat, cholesterol, and protein bilirubin. An inflamed liver does not perform these functions well, which brings about many of the symptoms, signs, and problems associated with any hepatitis. Liver diseases: NAFLD (Non-alcoholic fatty liver disease is a condition when there is an excess of fat in the liver of people who do not consume alcohol . Нe standard form of NAFLD is a benign condition called fatty liver when fat accumulates in the liver cells. NAFLD leads to hepatic steatosis NAFL (Nonalcoholic fatty liver disease), and aوٴects about 20% of patients and also is present in type 2 diabetes patients. NASH  is a condition where the liver sustains substantial damage, and the liver cells are gradually replaced by scar tissue impairing liver function. Some patients who develop cirrhosis may eventually require a liver transplant to remove the damaged liver. Hepatitis A B and C are viruses [6] that can impair liver function. Нe diseases caused by them are similar and leads to liver inflammation that can be severe or even life-threatening. Нere are eوٴective vaccines for hepatitis A and B but not for type C. Liver failure and hepatocellular carcinoma (HCC) are caused by alcohol abuse and obesity the leading causes of chronic liver diseases especially in the developed world. In advanced liver diseases  showed that liver cirrhosis is caused by HBV/HCV infection. Prevention of liver cirrhosis and HBV/HCV infection is necessary as HCC can result. Нe solution is to avoid alcohol, and drugs but treating the underlying causes i.e. is alcoholism and HBV/HCC related infections. HCC [8] is a serious problem because no treatment is available. Нe underlying causes for development of HCC are type 2 diabetes, alcoholism and chronic HBV/HCV infections lthat can lead to liver cirrhosis.

Authors can share their research in our journal through online portal by using this link: https://www.scholarscentral.org/submission/cytokine-biology.html 

With Regards,

Sarah Eve

Editorial Assistant

Journal of Cytokine Biology